Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve CBT BR3
- Development stage
- Preclinical
- Lead developer
- Cell Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Bifidobacterium breve* CBT BR3 is a probiotic bacterial strain, originally isolated from infant feces in South Korea, that is being investigated for its therapeutic potential in treating intestinal inflammation and metabolic disorders such as obesity. Developed by Cell Biotech, this live biotherapeutic has demonstrated efficacy in preclinical models of colitis by augmenting goblet cell regeneration and enhancing intestinal barrier function. In veterinary studies involving overweight and obese dogs, supplementation with CBT BR3 resulted in significant reductions in body weight, body condition scores, and metabolic markers including serum triglycerides and leptin. Its mechanism of action involves the modulation of gut microbiota composition and the production of metabolites that regulate immune responses and metabolic homeostasis. It is frequently studied as a single agent or in combination with other probiotics like *Lactiplantibacillus plantarum* CBT LP3.
- Other names
- Bifidobacterium breve BR3
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on Bifidobacterium breve CBT BR3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve CBT BR3.